Solara Active Pharma Sciences Second Quarter 2025 Earnings: EPS: ₹2.54 (vs ₹4.77 loss in 2Q 2024)
Solara Active Pharma Sciences (NSE:SOLARA) Second Quarter 2025 Results
Key Financial Results
- Revenue: ₹3.47b (down 18% from 2Q 2024).
- Net income: ₹80.1m (up from ₹171.6m loss in 2Q 2024).
- Profit margin: 2.3% (up from net loss in 2Q 2024).
- EPS: ₹2.54 (up from ₹4.77 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Solara Active Pharma Sciences Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are down 3.3% from a week ago.
Risk Analysis
Be aware that Solara Active Pharma Sciences is showing 1 warning sign in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:SOLARA
Solara Active Pharma Sciences
Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
Undervalued with reasonable growth potential.
